Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

Neurology

Volumn 77, Issue 21, 2011, Pages 1887-1895

  Martinelli, V ^a   Cocco, E ^b   Capra, R ^c   Salemi, G ^d   Gallo, P ^e   Capobianco, M ^f   Pesci, I ^g   Ghezzi, A ^h   Pozzilli, C ⁱ   Lugaresi, A ^j   Bellantonio, P ^k   Amato, M P ^l   Grimaldi, L M ^m   Trojano, M ⁿ   Mancardi, G L ^o   Bergamaschi, R ^p   Gasperini, C ^q   Rodegher, M ^a   Straffi, L ^a   Ponzio, M ^r   Comi, G ^a   Radaelli, M ^s   Esposito, F ^s   Moiola, L ^s   Colombo, B ^s   Rossi, P ^s   Marrosu, M G ^s   Frau, J ^s   Lorefice, L ^s   Coghe, G ^s   Savettieri, G ^s   Ragonese, P ^s   Cusimano, V ^s   Perini, P ^s   Rinaldi, F ^s   Vidali, A ^s   Bertolotto, A ^s   Malucchi, S ^s   Di Sapio, A ^s   Montanari, E ^s   Guareschi, A ^s   Rizzo, A ^s   Zaffaroni, M ^s   Baldini, S ^s   De Rossi, N ^s   Cordioli, C ^s   Rasia, S ^s   Salvetti, M ^s   Buttinelli, C ^s   Ausili Cefaro, L ^s   De Luca, Giovanna ^s   Tommaso, D ^s   Farina, D ^s   Fantozzi, R ^s   Ruggieri, S ^s   Hakiki, B ^s   Zipoli, V ^s   Portaccio, E ^s   Bartolozzi, M L ^s   Scandellari, C ^s   Stecchi, S ^s   Marchello, L P ^s   Palmeri, B ^s   Vitello, G ^s   Iaffaldano, P ^s   Lucchese, G ^s   Dattola, V ^s   Buccafusca, M ^s   Sola, P ^s   Simone, A M ^s   Barreca, F ^s   Patti, F ^s   Laisa, P ^s   Cavalla, P ^s   Masera, S ^s   Tavazzi, E ^s   Galgani, S ^s   Tedeschi, G ^s   Sacco, R ^s   Provinciali, L ^s   Maura, D ^s   Lus, G ^s   Alfieri, G ^s   Ticca, A ^s   Piras, M L ^s   Maimone, D ^s   Bianca, M ^s   Iudice, A ^s   Giro, M E ^s   Galeotti, M ^s   Florio, C ^s   Spitalieri, P ^s   La Mantia, L ^s   Motti, L ^s   Rottoli, M R ^s   Granella, F ^s   Solaro, C ^s   Scarpini, E ^s   Servillo, G ^s   Cavaletti, G ^s   more..

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c SPEDALI CIVILI   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^f SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^g Hospital of Fidenza   (Italy)

^h Hospital of Gallarate   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j UNIVERSITY OF CHIETI   (Italy)

^k IRCCS NEUROMED   (Italy)

^l UNIVERSITY OF FLORENCE   (Italy)

^m Neurophysiology Unit   (Italy)

ⁿ UNIVERSITY OF BARI   (Italy)

^o UNIVERSITY OF GENOA   (Italy)

^p C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^q SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^r UNIVERSITY OF PAVIA   (Italy)

^s NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; CANCER MORTALITY; CANCER RISK; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; DISEASE ASSOCIATION; DOSE RESPONSE; EARLY DIAGNOSIS; EARLY INTERVENTION; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 82955225355     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318238ee00     Document Type: Article

References (35)

1. Neuhaus O, Kieseier BC, Hartung HP. Mechanisms of mitoxantrone in multiple sclerosis: What is known? J Neurol Sci 2004;223:25-27. (Pubitemid 38903257)
2. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118. (Pubitemid 27090928)
3. Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360:2018-2025. (Pubitemid 36026580)
4. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909-913.
5. Vicari AM, Ciceri F, Folli F, et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998;12:441-442. (Pubitemid 28138231)
6. Brassat D, Recher C, Waubant E, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002;59:954-955.
7. Cattaneo C, Almici C, Borlenghi E, Motta M, Rossi G. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia 2003;17: 985-986. (Pubitemid 36626331)
8. Heesen C, Bruegmann M, Gbdamosi J, Koch E, Mönch A, Buhmann C. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult Scler 2003;9:213-214. (Pubitemid 36426997)
9. Tanasescu R, Debouverie M, Pittion S, Anxionnat R, Vespignani H. Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient. J Neurol 2004; 251:762-763. (Pubitemid 38824028)
10. Novoselac AV, Reddy S, Sanmugarajah J. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia 2004;18: 1561-1562. (Pubitemid 39264087)
11. Voltz R, Starck M, Zingler V, Strupp M, Kolb HJ. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: A case report out of 644 treated patients. Mult Scler 2004; 10:472-474. (Pubitemid 39117348)
12. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21: 2123-2137. (Pubitemid 46606361)
13. Ghalie RG, Mauch E, Edan G, et al. A study of therapyrelated acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002;8:441-445.
14. Ledda A, Caocci G, Spinicci G, Cocco E, Mamusa E, La Nasa G. Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. Leukemia 2006;20:2217-2218. (Pubitemid 44782862)
15. Cordioli C, Cattaneo C, Capra R. Analysis of incidence, risk factors and prognosis of acute promyelocytic leukaemia related to mitoxantrone therapy in multiple sclerosis. Neurology 2007;68(suppl 1):A276. Abstract.
16. Cocco E, Marchi P, Sardu C, et al. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler 2007;13:975-980. (Pubitemid 351541431)
17. Bosca I, Pascual AM, Casanova B, Coret F, Sanz MA. Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone. Neurology 2008;71:457-458.
18. Capobianco M, Malucchi S, Ulisciani S, et al. Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. Neurol Sci 2008;29:185-187. (Pubitemid 352003657)
19. Pascual AM, Téllez N, Boscá I, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler 2009;15:1303-1310.
20. Ellis R, Boggild M. Therapy-related acute leukaemia with Mitoxantrone: What is the risk and can we minimise it? Mult Scler 2009;15:505-508.
21. Esposito F, Radaelli M, Martinelli V, et al. Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 2010;16:1490-1499.
22. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74: 1463-1470.
23. Kröger N, Damon L, Zander AR, et al. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transplant 2003;32:1153-1157. (Pubitemid 38072328)
24. Rivera V, Weinstock-Guttman B, Beagan J, Al-Sabbagh A, Bennett R, Dangond F. Final results from the Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis study. Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 9 -12, 2009, Dusseldorf.
25. Hasan SK, Buttari F, Ottone T, et al. Risk of acute promyelocytic leukemia in multiple sclerosis: Coding variants of DNA repair genes. Neurology 2011;76:1059-1065.
26. Brownson RC, Novotny TE, Perry MC. Cigarette smoking and adult leukemia: A meta-analysis. Arch Intern Med 1993;153:469-475.
27. Lebrun C, Debouverie M, Vermersch P, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler 2008;14:399-405. (Pubitemid 351676435)
28. Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T. Cancer risk among patients with multiple sclerosis and their parents. Neurology 2009;72:1170-1177.
29. Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci 2009;277(suppl 1): S42-S45.
30. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases. Lancet Neurol 2010;9:438-446.
31. Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients' benefit-risk preferences: Serious adverse event risks versus treatment efficacy. J Neurol 2009;256:554-562.
32. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.
33. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875-1891.
34. Le Page E, Leray E, Edan G, for the French Mitoxantrone Safety Group. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: A 5-year prospective study. Mult Scler 2011;17:867-875.
35. Ray A. Beyond debacle and debate: Developing solutions in drug safety. Nature Rev Drug Discov 2009;8:775-779.